Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Official Title

Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.


This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Trial Description

Primary Outcome:

  • Number of participants with adverse events leading to permanent discontinuation of study intervention
  • Number serious adverse events reported for all participants
B9991046 is a master protocol that will consist of sub-studies from the following parent studies: B9991001
  • NCT02603432 B9991004
  • NCT02554812 B9991005
  • NCT02584634 B9991009
  • NCT02580058 B9991023
  • NCT03317496 B9991025
  • NCT03330405 B9991027
  • NCT03472560 B9991032
  • NCT03565991

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society